Pfizer Inc.
PFE | NYSE
$27.74
+$0.08 (+0.29%)
At close: Sep 21, 2026, 4:02 PM ET
$27.75
+$0.01 (+0.04%)
After-hours:
Sep 21, 2026, 7:52 PM ET
Company Profile
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Albert Bourla | Chairman of the Board & Chief Executive Officer |
| David Denton | Executive Vice President & Chief Financial Officer |
| Dennis Hancock | Executive VP & Chief Information Officer |
| Douglas Lankler | Executive Vice President & Chief Legal Officer |
| Aamir Malik | Executive Vice President & Chief U.S. Commercial Officer |
| Cecile Guegan | Interim CFO & Executive VP |
| Chris Boshoff FMedSci | Chief Scientific Officer and President of Research & Development |
| Francesca DeMartino | Chief Investor Relations Officer |
| Jeffrey Settleman | Chief Scientific Officer of Oncology |
| Jennifer Damico | Senior Vice President, Controller & Principal Accounting Officer |
| Michael S. Vincent | Senior Vice President and Chief Scientific Officer of Inflammation & Immunology |
| Payal Sahni Becher | Chief People Experience Officer & Executive Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 4 | Filing |
| Aug 31, 2026 | N-PX | Filing |
| Aug 28, 2026 | 3 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 13, 2026 | 13F-HR | Quarterly report filed by institutional managers, ... |
| Aug 12, 2026 | 4 | Filing |
| Aug 06, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
| Aug 04, 2026 | 10-Q | Quarterly Report |
Pfizer Inc.
| Country | United States |
| IPO Date | May 31, 1972 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,000 |
| CEO | Albert Bourla |
Contact Details
66 Hudson Boulevard East New York City,
New York 10001-2192 United States
Stock Details
| Ticker Symbol | PFE |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000078003 |
| CUSIP Number | 717081103 |
| ISIN Number | US7170811035 |
| SIC Code | 2834 |
Recent News
- 20 hours ago / seekingalpha.comPfizer: The 10-Year Is At 5%, And I'm Still Buying This 6%+ Yield
- 1 day ago / fool.comPfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?
- 2 days ago / fool.comIs Pfizer an Excellent Dividend Stock to Buy?
- 3 days ago / fool.com3 Dividend Stocks to Buy and Hold for 10 Years
- 3 days ago / 247wallst.comPfizer's Dividend Yield Is Enormous. But Is the Payout Still Growing?
- 5 days ago / fool.comPfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.
- 6 days ago / zacks.comIs Trending Stock Pfizer Inc. (PFE) a Buy Now?
- 8 days ago / seekingalpha.comPfizer Inc. (PFE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 8 days ago / marketbeat.comPfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage
- 8 days ago / zacks.comCan Pfizer Overcome Its COVID and Patent Cliff Headwinds?
Add to Watchlist
Select watchlists to add or remove PFE